What happened
Despite upbeat recent developments, shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) fell 15.3% during Wednesday’s session. The biotech reported solid progress with clinical-stage candidates, but a steep drop in Relistor revenue weighed on the stock.
